XERF is a noninvasive monopolar radiofrequency device. Its treatment tip delivers 6.78 MHz and 2 MHz energy in a programmed pulse while cooling the skin surface. The goal in aesthetic use is controlled heating for modest skin tightening. The depth reached and the result for one person cannot be read from the frequencies alone.
What happens when the tip touches skin?
Unlike a laser, XERF does not aim light at pigment. Radiofrequency current passes from the treatment tip through tissue to a return electrode. Electrical resistance turns part of that energy into heat. The manufacturer describes two frequencies, 6.78 MHz and 2 MHz, selectable depth and intensity settings, and cryogen cooling at the surface. Cooling matters because the epidermis needs protection while tissue below is heated.
“Dual frequency” is a device description, not a promise that a particular layer will tighten. In the 39-person prospective study, investigators used different settings for different facial zones. The paper explicitly says it did not verify effects on particular deep structures, including the SMAS, in human tissue. Ask a provider which part of your concern they intend to treat and how they will judge whether it changed.
What do the studies actually measure?
The evidence comes in layers. A 2024 pig-skin experiment measured heating and tissue changes under controlled conditions. That helps explain a possible mechanism; it does not show how a human face will look months later. A separate histology letter was later corrected to disclose that several authors worked for the manufacturer. Disclosures do not erase the observations, but they matter when weighing how independently a result has been tested.
The human evidence is more relevant to a patient. At four sites, 39 people received two XERF sessions and were assessed after the final treatment at 30 and 90 days. Clinician ratings and patient satisfaction improved, but there was no untreated or alternative-device control group. A different 16-person retrospective report assessed one treatment with follow-up through three months. It also found changes in selected measurements and questionnaires. That design cannot establish an expected result for a new patient.
Two human reports are encouraging, but both are small, short-term, and lack a randomized comparison. They support a consultation about XERF; they do not support a guaranteed lift, a permanent result, or a claim that XERF beats another device.
Is XERF a laser or an FDA-approved facelift alternative?
No. XERF is radiofrequency, and a noninvasive treatment does not reproduce surgery. The FDA 510(k) record K251327 clears the device for electrocoagulation and hemostasis in dermatologic and general surgical procedures. It does not list wrinkle reduction or lifting as the cleared indication. “FDA cleared” and “FDA approved for a facelift-like result” are different statements.
If unwanted hair is the actual problem, start with laser hair removal. If your concern is mild laxity or texture, ask whether radiofrequency is reasonable for your skin and whether a different approach could answer it better. Our comparison of tightening devices explains the evidence gap between product names.
Questions worth bringing to a consultation
- Which specific change could XERF reasonably make for me, and which concern would it leave alone?
- Who chooses the settings and how is skin response monitored during treatment?
- What evidence supports the suggested number of visits for my concern?
- How will before-and-after photographs be standardized, and when will we reassess?
Appointments discussed on this site are at a participating Garden City location. Use Ask about a free consultation or call the number in the sticky bar. Do not include medical records in the form.
Sources and how to read them
We distinguish device descriptions, regulatory records, human clinical reports, and research on radiofrequency as a category. Findings in a small study or another device should not be treated as a prediction for one XERF patient.
- Cynosure Lutronic, XERF product information
- Weiss et al., prospective XERF study, 2026
- Erlich et al., retrospective XERF study, 2026
- Park et al., porcine RF study, 2024
- Hong et al. correction, manufacturer affiliations, 2026
- FDA, XERF 510(k) K251327 record
Researched by Detroit Beauty Connect, September 27, 2026. Informational only; this page is not a diagnosis, a treatment plan, or a claim of clinician review. Ask the treating professional for advice specific to you.